Population Fisher information matrix and optimal design of discrete data responses in population pharmacodynamic experiments

Ogungbenro, Kayode; Aarons, Leon
August 2011
Journal of Pharmacokinetics & Pharmacodynamics;Aug2011, Vol. 38 Issue 4, p449
Academic Journal
In the recent years, interest in the application of experimental design theory to population pharmacokinetic (PK) and pharmacodynamic (PD) experiments has increased. The aim is to improve the efficiency and the precision with which parameters are estimated during data analysis and sometimes to increase the power and reduce the sample size required for hypothesis testing. The population Fisher information matrix (PFIM) has been described for uniresponse and multiresponse population PK experiments for design evaluation and optimisation. Despite these developments and availability of tools for optimal design of population PK and PD experiments much of the effort has been focused on repeated continuous variable measurements with less work being done on repeated discrete type measurements. Discrete data arise mainly in PDs e.g. ordinal, nominal, dichotomous or count measurements. This paper implements expressions for the PFIM for repeated ordinal, dichotomous and count measurements based on analysis by a mixed-effects modelling technique. Three simulation studies were used to investigate the performance of the expressions. Example 1 is based on repeated dichotomous measurements, Example 2 is based on repeated count measurements and Example 3 is based on repeated ordinal measurements. Data simulated in MATLAB were analysed using NONMEM (Laplace method) and the glmmML package in R (Laplace and adaptive Gauss-Hermite quadrature methods). The results obtained for Examples 1 and 2 showed good agreement between the relative standard errors obtained using the PFIM and simulations. The results obtained for Example 3 showed the importance of sampling at the most informative time points. Implementation of these expressions will provide the opportunity for efficient design of population PD experiments that involve discrete type data through design evaluation and optimisation.


Related Articles

  • Development and evaluation of a generic physiologically based pharmacokinetic model for children. Edginton, Andrea N.; Schmitt, Walter; Willmann, Stefan // Clinical Pharmacokinetics;2006, Vol. 45 Issue 10, p1013 

    Background: Clinical trials in children are being encouraged by regulatory authorities in light of the immense off-label and unlicensed use of drugs in the paediatric population. The use of in silico techniques for pharmacokinetic prediction will aid in the development of paediatric...

  • PII-60. Hilbert, J.; Schnee, J.; Rummerstorfer, U.; Jilma, B. // Clinical Pharmacology & Therapeutics;Feb2006, Vol. 79 Issue 2, pP52 

    Background/aims: BIWH 3 is a recombinant pyro-glu monocyte chemotactic protein-1 (MCP-1). Based on arteriogenic effects of MCP-1 in animals, MCP-1 was developed for critical limb ischemia. This study investigated safety, tolerability, and PK of BIWH 3 after single 1-hr iv infusions of 20 ng/kg -...

  • The Influence of Underlying Assumptions on Evaluating the Relative Merits of Concentration-Controlled and Dose-Controlled Trials. Lledó-García, R.; Hennig, S.; Karlsson, M. O. // Clinical Pharmacology & Therapeutics;Jul2009, Vol. 86 Issue 1, p70 

    The objective of this study was to assess the relative performances of concentration-controlled trial (CCT) and dose-controlled clinical trial (DCT) designs with varying (i) interindividual variability (IIV) in clearance (CL), (ii) relative clinical importance of rejection and infection...

  • Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. Anton Y. Peleg; Brian A. Potoski; Rhonda Rea; Jennifer Adams; Jigme Sethi; Blair Capitano; Shahid Husain; Eun J. Kwak; Sunil V. Bhat; David L. Paterson // Journal of Antimicrobial Chemotherapy (JAC);Jan2007, Vol. 59 Issue 1, p128 

    Objectives: Tigecycline has shown in vitro activity against Acinetobacter baumannii. Yet, published clinical experience with tigecycline use outside clinical trials is lacking. We describe, for the first time, bloodstream infection caused by tigecycline-non-susceptible A. baumannii occurring in...

  • Maraviroc. Carter, Natalie J.; Keati, Gillian M. // Drugs;2007, Vol. 67 Issue 15, p2277 

    Maraviroc is a specific, slowly reversible, noncompetitive, small-molecule antagonist of the CCR5 chemokine receptor, which also serves as an HIV-1 coreceptor. By acting as an antagonist at the CCR5 coreceptor, maraviroc inhibits HIV-1 from entering host cells. Clinical data for maraviroc are...

  • The Clinical Significance of Variations in Ethanol Toxicokinetics. Pizon, Anthony F.; Becker, Charles E.; Bikin, Dale // Journal of Medical Toxicology;Jun2007, Vol. 3 Issue 2, p63 

    Introduction: Many variables affect the interpretation of an isolated ethanol level in an acutely intoxicated patient. This review demonstrates the significant variability in metabolism and elimination of ethanol, how it can differ between individuals, and the clinical importance of these...

  • Effects of nitazoxanide on pharmacokinetics and pharmacodynamics of a single dose of warfarin. Vets, Eva; Rossignol, Jean-Francois; Jackson, Anthony Shane // American Journal of Health-System Pharmacy;5/1/2009, Vol. 66 Issue 9, p838 

    Purpose. The effects of nitazoxanide on warfarin pharmacokinetics and pharmacodynamics are examined. Methods. This was a Phase I, single-center, open-label, randomized, two-way, crossover study. Secondary endpoints included an evaluation of the effect of nitazoxanide on coagulation parameters...

  • Fluvoxamine significantly alters tizanidine pharmacokinetics.  // Reactions Weekly;6/19/2004, Issue 1006, p4 

    Reports on a study conducted by researchers from Finland on the effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of tizanidine. Dosage of fluvoxamine administered to the study's participants; Increase in the pharmacodynamic responses to tizanidine following fluvoxamine...

  • Pharmacologic Advances in the Global Control and Treatment of Malaria: Combination Therapy and Resistance. Nyunt, M. M.; Plowe, C. V. // Clinical Pharmacology & Therapeutics;Nov2007, Vol. 82 Issue 5, p601 

    Combination drug therapy for malaria is recommended both to prevent and to overcome drug resistance. Drug combinations developed for use in Asia are being deployed in Africa, where higher rates of malaria affect the therapeutic and public health objectives of malaria chemotherapy as well as drug...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics